By: Jason Bacharach, MD; Jella An, MD
This no-fee CME webinar provides valuable information on the efficacy, safety, indications, optimal patient selection, and surgical pearls for microinvasive glaucoma surgery (MIGS).
Supported through an educational grant from New World Medical.
At the completion of this educational activity, the participating ophthalmologist will be better able to:
•Identify and understand the advantages and disadvantages of trabecular, supraciliary, and subconjunctival microinvasive glaucoma surgery (MIGS) procedures.
•Describe the efficacy and safety of trabecular meshwork (TM) and Schlemm canal MIGS procedures.
•Identify the patient characteristics that favor the use of TM and Schlemm canal MIGS procedures.
•Adopt optimal surgical techniques when performing TM and Schlemm canal MIGS procedures.
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.25Â AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Jason Bacharach, MD
Founding Partner & Director of Research
North Bay Eye Associates Inc.
Sonoma County, California
Co-Director of Glaucoma Division
California Pacific Medical Center
San Francisco, California
Jella An, MD
Medical Director, University Eye Institute East
Director, Glaucoma Service and Fellowship Program
Department of Ophthalmology
University of Missouri
Columbia, Missouri
Jason Bacharach, MD, hand or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/ Speaker’s Bureau: Aerie, Allergan, Bausch & Lomb, Eyepoint, Glaukos, Gore, New World Medical, Nicox, Novartis, Ocular Therapeutix, and Santen.
Jella An, MD, and or spouse has had a financial agreement or affiliation during the past year with the following commercial in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Iridex, New World Medical.
EDITORIAL SUPPORT
•Erin K. Fletcher, MIT, director of compliance and education, Evolve, has no financial relationships with commercial interests.
•Susan Gallagher-Pecha, director of client services and project management, Evolve, has no financial relationships with commercial interests.
•Cassandra Richards, director of education development, Evolve, has no financial relationships with commercial interests.
•Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
By: Jason Bacharach, MD; Jella An, MD